Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations.

ABSTRACT:

Aim/objective/introduction

Cytokine storm or cytokine release syndrome (CRS) is inevitable in severe and critically ill patients with novel coronavirus disease-2019 (COVID-19). This review aimed to discuss current therapeutic options for the management of CRS in COVID-19.

Background

Cytokine storm is caused by the colossal release of proinflammatory cytokines [e.g., IL (interleukin)-2, IL-6, IL-8 TNF (tumor necrosis factor)-α, etc.] causing dysregulated, hyperimmune response. This immunopathogenesis leads to acute lung injury and acute respiratory distress syndrome (ARDS). Targeting cytokine storm with the therapies that are already available in India with the support of published guidelines and consensus can assist in achieving a better outcome in COVID-19.

Review result

SUBMITTER: Mehta Y 

PROVIDER: S-EPMC7435090 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature